Back to News
Market Impact: 0.2
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
Source: PR Newswire
Legal & Litigation
Schall, Brown & Schwartz LLP reminded investors of a class action lawsuit against ARS Pharmaceuticals (NASDAQ: SPRY), alleging violations of Sections 10(b) and 20(a). The provided article excerpt gives no further details on the allegations, potential damages, or case developments.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.20
Ticker Sentiment
SPRY-0.70
More News
- Nvidia's $20 billion Groq deal faces lawsuit alleging startup's stockholders were shortchanged
- It’s ‘more likely than not’ humanity loses control: Former AI insiders testify safety fixes may be ‘duct tape that will fall off later’
- Anthropic, OpenAI, Google and Meta execs set to testify at NYC Council hearing on AI risks
- US supreme court hears big oil's bid to block climate damage lawsuits
- Liquidia Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Liquidia (LQDA)
- US Supreme Court weighs bid by oil companies to avoid climate lawsuit